Promising Blood Test Shows High Accuracy in Early Breast Cancer Detection
A new blood test developed by Astrin Biosciences, called Certitude, is demonstrating significant promise in the early detection of breast cancer, possibly offering a less invasive and more accessible screening option for millions of women. following national Breast Cancer Month in October, the company unveiled compelling data at the San Antonio Breast Cancer Symposium, highlighting the test’s ability to identify cancer across various stages and subtypes with remarkable accuracy.
Rising Incidence and the Need for Improved Screening
Breast cancer remains a significant health concern, with projections indicating that approximately 316,950 women in the United States will be diagnosed with the disease in 2025. Early detection is crucial for improving treatment outcomes and survival rates, yet current screening methods have limitations, particularly for women with dense breast tissue.
Certitude: A Novel Protein-Based Approach
astrin Biosciences has been dedicated to developing Certitude, a protein-based blood test designed to enhance breast cancer screening. The recent study, involving over 500 women with and without breast cancer, revealed impressive results. The test achieved an overall sensitivity of over 84% in detecting cancer, with a sensitivity of 92% and specificity of 93% across all stages and subtypes of the disease.
remarkable Performance in Challenging Cases
Notably, Certitude demonstrated particularly high sensitivity – exceeding 90% – in detecting triple-negative breast cancer, an aggressive form of the disease often more challenging to treat. Furthermore, the test maintained a high level of accuracy (92.3% sensitivity and 92.6% specificity) even in participants without breast cancer, minimizing the risk of false positives.
Addressing the Challenges of Dense Breast Tissue
A key advantage of Certitude lies in its consistent performance nonetheless of breast density. “It’s tougher to detect breast cancer in women with dense breast tissue,” explains Jamie LaMontagne, CEO of Astrin Biosciences. “Sometimes traditional forms of early detection and mammograms don’t pick it up.” Dense breast tissue can obscure cancerous growths on mammograms, reducing sensitivity to as low as 30%. Certitude’s ability to overcome this limitation offers a significant advancement in screening capabilities.
Early Stage Detection: A Unique Strength
Dr.Justin Drake,Chief Science Officer at Astrin Biosciences,emphasizes that Certitude excels at detecting cancer in its earlier stages (Stages 0-2). “Current methods are good at detecting cancer in later stages, but what makes this test unique is picking it up earlier,” he stated. This early detection capability could lead to more timely interventions and improved patient outcomes.
A Complementary, Not Replacement, Screening Tool
While the results are encouraging, researchers stress that Certitude is not intended to replace existing screening methods like mammograms and biopsies. “The test is meant to provide more insight into earlier stages of screening, and isn’t replacing existing detection tools on the market,” Dr. Drake clarified.”If the test is 99.9% positive in an early stage, this is a flag for patients to seek verification through procedures like mammograms or biopsies.”
Reducing Healthcare Burden and Improving Access
the progress of Certitude also aims to alleviate the burden on the healthcare system and improve access to screening.Mammograms and biopsies can be costly, potentially reaching thousands of dollars, and often involve lengthy wait times – two to four weeks on average, and even longer in rural areas. Certitude currently has a turnaround time of two weeks, with the company working to further expedite the process.By potentially reducing the need for unnecessary MRIs and biopsies, the test could save patients time and money.
Looking Ahead: FDA Trials and Future Availability
Astrin Biosciences is now preparing for independent testing of Certitude, followed by FDA trial testing, anticipated to begin by the end of 2027 or early 2028. If accomplished, this innovative blood test could revolutionize breast cancer screening, offering a more accessible, accurate, and timely method for detecting this devastating
Related reading